NCPC(SH:600812)2014-04-25 16:00Financial Performance - Operating revenue decreased by 12.39% to CNY 2.94 billion from CNY 3.36 billion in the same period last year[9] - Net profit attributable to shareholders increased by 34.07% to CNY 6.48 million compared to CNY 4.84 million in the previous year[9] - Basic and diluted earnings per share increased by 25.00% to CNY 0.005[9] - Operating profit for the period was CNY 5,134,684.76, a significant recovery from a loss of CNY 38,352,421.83 in the previous year[28] - Net profit attributable to the parent company was CNY 6,484,884.87, up from CNY 4,837,091.52 year-over-year, reflecting a positive growth trend[28] - Operating revenue for the current period is ¥1,776,854,593.19, a decrease of 9.94% from ¥1,973,415,810.22 in the previous period[31] - Net profit for the current period is ¥23,807,259.99, compared to ¥19,987,049.64 in the previous period, reflecting a growth of 19.1%[31] Assets and Liabilities - Total assets increased by 2.22% to CNY 14.88 billion compared to the end of the previous year[9] - Total liabilities increased to CNY 8,053,782,154.12 from CNY 7,092,967,801.66, marking a growth of approximately 13.56%[20] - Non-current assets totaled CNY 9,030,210,156.56, up from CNY 8,950,733,777.58, indicating a growth of approximately 0.89%[20] - The company reported a total asset value of CNY 14,882,685,062.04, an increase from CNY 14,560,088,463.99, reflecting a growth of about 2.21%[20] - Total assets increased to CNY 13,316,148,533.68 from CNY 12,418,207,332.51, indicating a growth of 7.2%[25] - Total liabilities rose to CNY 8,215,383,313.13, compared to CNY 7,341,249,371.95, marking an increase of 11.9%[25] Cash Flow - The company reported a net cash flow from operating activities of CNY -132.25 million, showing a slight improvement from CNY -135.10 million in the previous year[9] - Cash inflow from operating activities totaled ¥2,142,521,973.39, slightly up from ¥2,064,905,893.31 in the previous period[33] - Cash outflow from operating activities increased to ¥2,274,768,850.98 from ¥2,200,001,699.40, resulting in a net cash flow from operating activities of -¥132,246,877.59[33] - Cash inflow from financing activities rose significantly to ¥1,597,693,023.54, compared to ¥797,237,618.75 in the previous period[35] - The ending balance of cash and cash equivalents is ¥1,171,777,030.65, down from ¥1,749,000,509.16 in the previous period[35] Shareholder Information - The number of shareholders totaled 83,239, with the top ten shareholders holding a combined 70.39% of shares[10] - The largest shareholder, Jizhong Energy Group, holds 25.39% of shares, with 175 million shares pledged[10] - The total equity attributable to shareholders increased to CNY 5,100,765,220.55 from CNY 5,076,957,960.56, a growth of 0.5%[25] Operational Changes and Commitments - The company is appealing a court ruling related to a vitamin C antitrust case in the U.S., which may impact future operations[12] - The company committed to focus on pharmaceutical logistics and related product logistics trade, ceasing coal, coke, steel, and PVC trading to avoid competition with Jizhong Energy Group and Huabei Pharmaceutical Group[13] - The company will not produce or register the pesticide products Chuanlei Mei Su and Thiazine after their respective production approvals expire, as the production volume of Chuanlei Mei Su is small[13] - The company has committed to minimizing related party transactions during the period of direct or indirect shareholding by Huabei Pharmaceutical Group[14] - The company will sign a long-term trademark licensing agreement with Huabei Pharmaceutical Group after the current agreements expire, with a minimum duration of 5 years[14] - The company will focus on the development of pharmaceutical logistics and related fields, aligning with market trends and protecting minority shareholder interests[14] - The company will ensure that any related party transactions are conducted at market prices, maintaining fairness in all dealings[14]